Arix Bioscience plc: Update on LogicBio Proposed Initial Public Offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET
                               ABUSE REGULATION NO.596/2014

    Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company
supporting medical innovation, today notes that LogicBio Therapeutics Inc.("LogicBio") has
filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange
Commission (the "SEC") relating to a proposed initial public offering in the United States
of shares of its common stock.

    The registration statement discloses an indicative pricing range for the proposed
offering of U.S.$12.00- U.S.$14.00 per common share. This would represent an increase in
value of Arix's current shareholding in LogicBio (compared to the GBP4.9 million sterling
holding value) of GBP15.9 - GBP19.4 million[1]. The proposed maximum aggregate offering
amount specified in the filing is U.S.$75.0 million, which assumes that the offering price
is at the midpoint of the indicative pricing range and does not include the underwriters'
option to purchase additional common shares.

    Arix has indicated an interest in purchasing common shares in the offering, subject to
agreement with the underwriters.

    The registration statement can be accessed through the SEC's EDGAR database. The
registration statement relating to the shares of common stock has been filed with the SEC
but has not yet become effective. The shares may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective.

    This announcement does not constitute an offer to sell or the solicitation of an offer
to buy securities, and shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that jurisdiction.

    The securities referred to in this release are to be offered only by means of a
prospectus. When available, copies of the preliminary prospectus can be obtained from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at
[email protected].

    About Arix Bioscience plc  

    Arix Bioscience plc is a global healthcare and life science company supporting medical
innovation. Headquartered in London and with an office in New York, Arix Bioscience
sources, finances and builds world class healthcare and life science businesses addressing
medical innovation at all stages of development. Operations are supported by privileged
access to breakthrough academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.

    Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

    About LogicBio 

    LogicBio Therapeutics is a genome editing company focused on developing medicines to
durably treat rare diseases in patients with significant unmet medical needs using
GeneRide(TM), its proprietary technology platform. GeneRide(TM) enables the site-specific
integration of a therapeutic transgene, in a nuclease-free and promotorless approach by
relying on the native process of homologous recombination to drive lifelong expression.
Headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines
that will transform the lives of pediatric patients and their families.

    References:

    1. At exchange rate on 9 October 2018  

<pre>

    Enquiries


    For more information on Arix, please contact:


    Arix Bioscience plc
    Charlotte Parry, Head of Investor Relations
    +44(0)20-7290-1072
    [email protected]

    Optimum Strategic Communications
    Mary Clark, Supriya Mathur
    +44(0)203-714-1787
    [email protected]

    Burns McClellan (US Media & IR Enquiries)
    Nancie Steinberg, Bill Slattery Jr.
    +1-212-213-0006
    [email protected]
</pre>     


The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.